All In Biotech

Drug Trial Radar · NCT07293351

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC)

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 474 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

474

Planned (sponsor's estimate)

Start

Mar 26, 2026

Primary completion

Nov 28, 2029

Study completion Nov 26, 2031

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Dec 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC)

Conditions

  • Advanced Renal Cell Carcinoma (RCC)

Interventions

  • PumitamigDrug

    Specified dose on specified days

  • IpilimumabDrug

    Specified dose on specified days

  • CabozantinibDrug

    Specified dose on specified days

  • CasdatifanDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Up to approximately 2 years from end of treatment
  2. Number of participants with serious adverse events (SAEs) (as per Common Terminology Criteria for Adverse Events v5 (CTCAE v5))Time frame: Up to approximately 2 years from end of treatment
  3. Number of participants with AEs meeting protocol-defined dose-limiting toxicity (DLT) criteriaTime frame: Up to day 21 from first dose
  4. Number of participants with AEs leading to discontinuationTime frame: Up to approximately 2 years from end of treatment
  5. Number of participants with AEs leading to deathTime frame: Up to approximately 2 years from end of treatment
  6. Objective response rate (ORR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessmentTime frame: Up to approximately 2 years from end of treatment

Locations

95 sites in 20 countries. Site status is shown where the registry gives one.

  • Local Institution - 0178

    Palo Alto, California · Not yet recruiting

  • Local Institution - 0117

    New Haven, Connecticut · Not yet recruiting

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia · Recruiting

  • Local Institution - 0177

    Miami, Florida · Not yet recruiting

  • Local Institution - 0126

    Orlando, Florida · Not yet recruiting

  • Local Institution - 0170

    Fort Wayne, Indiana · Not yet recruiting

  • University Of Iowa Hospitals And Clinics

    Iowa City, Iowa · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Local Institution - 0176

    Big Rapids, Michigan · Not yet recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Local Institution - 0135

    Cincinnati, Ohio · Not yet recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • MUSC Hollings Cancer Center

    Charleston, South Carolina · Recruiting

  • Carolina Urologic Research Center, LLC

    Myrtle Beach, South Carolina · Recruiting

  • Local Institution - 0158

    Salt Lake City, Utah · Withdrawn

  • Local Institution - 0095

    Seattle, Washington · Not yet recruiting

  • Instituto Medico Especializado Alexander Fleming

    Buenos Aires, Argentina · Recruiting

  • Local Institution - 0156

    Buenos Aires, Argentina · Not yet recruiting

  • Asociación de Beneficencia Hospital Sirio Libanés

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Macquarie University

    North Ryde, New South Wales, Australia · Recruiting

  • GenesisCare St Leonards

    St Leonards, New South Wales, Australia · Recruiting

  • Mater Misericordiae Limited

    Brisbane, Queensland, Australia · Recruiting

  • Local Institution - 0011

    Herston, Queensland, Australia · Not yet recruiting

  • Local Institution - 0004

    Heidelberg, Victoria, Australia · Not yet recruiting

  • Cabrini Hospital - Malvern

    Malvern, Victoria, Australia · Recruiting

  • Local Institution - 0007

    Calgary, Alberta, Canada · Not yet recruiting

  • Local Institution - 0189

    Edmonton, Alberta, Canada · Not yet recruiting

  • Local Institution - 0109

    Montreal, Quebec, Canada · Withdrawn

  • Local Institution - 0009

    Montreal, Quebec, Canada · Not yet recruiting

  • Local Institution - 0006

    Québec, Quebec, Canada · Not yet recruiting

  • Pontificia Universidad Catolica de Chile (PUC)

    Santiago, Chile · Recruiting

  • Local Institution - 0105

    Santiago, Santiago Metropolitan, Chile · Not yet recruiting

  • Bradfordhill

    Santiago, Santiago Metropolitan, Chile · Recruiting

  • Local Institution - 0144

    Beijing, China · Not yet recruiting

  • Local Institution - 0143

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Local Institution - 0157

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Local Institution - 0182

    Guangzhou, Guangdong, China · Not yet recruiting

  • Local Institution - 0145

    Tianjin, Hebei, China · Not yet recruiting

  • Local Institution - 0187

    Harbin, Heilongjiang, China · Not yet recruiting

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.